Comparisons of cancer staging systems should be based on overall performance in the population Kathleen F Kerr 1 , Michael LeBlanc 2 and Holly Janes 2 In a recent article in the journal, Kattan and Gerds 1 propose a method for evaluating whether a new cancer staging system is more prognostic than the existing staging system. The proposed method first checks whether both the ''old'' or established staging system and the ''new'' candidate staging system meet a minimum level of prognostic performance in the patient population. If they do, the proposed method then evaluates the prognostic performance of one staging system within levels defined by the other. Drawing on our background in evaluating the prognostic capacity of biomarkers, we caution that this approach does not reliably assess which staging system is more prognostic.
The Kattan-Gerds method relies on a ''reclassification table'' that cross-tabulates patients using the old and new staging systems (see Table 1 for an example). The method examines the prognostic performance of the new staging system within levels of the old staging system. (Or, if the new system has fewer levels than the old system, the old system is instead evaluated within levels of the new system.) If the new system meets a minimum level of overall population performance (its c-index exceeds 0.5) and is prognostic within every level of the old system, the Kattan-Gerds algorithm prescribes that the new system should be adopted as the more prognostic staging system. Table 1 gives a simple, hypothetical example showing that a new system can be prognostic in every level of the old system but have inferior prognostic capacity in the population overall. In the example, the new System B is prognostic in each level of old System A (c-index = 0.71), yet the population prognostic capacity is lower for System B (c-index = 0.62) than for System A (cindex = 0.74). According to the Kattan-Gerds method, we should abandon the old system A and adopt the new system B, despite the fact that B is less prognostic overall than A. (In fact, the approach could have one going in circles, with each system deemed better than the other according to the proposed procedure.)
Our view is that a head-to-head comparison of the competing systems should be based on their performances in the patient population. One can choose one's preferred measure and compare that measure between the systems. For example, using the c-index favored by Kattan and Gerds for the example in Table 1 , the old system A (c-index = 0.74) is superior to the new system B (c-index = 0.62) in the head-to-head comparison of population performance. Table 1 gives the survival times of patients in each group so that readers can explore the example on their own. In addition, we provide an R function (http://faculty.washington.edu/katiek/software.html) that simulates data with a similar structure with exponential distributions of survival times. One can specify sample sizes to be arbitrarily large and get the same qualitative result. The results from applying the Kattan-Gerds method to the example in Table 1 are not attributable to small sample sizes or the particular choice of survival distribution. Nor do results depend on the choice of the c-index as the measure of prognostic capacity. For example, if prognostic capacity is measured by contrasting mean survival time across levels, we arrive at the same conclusion: one system can be prognostic within every level of another system and yet be less prognostic overall.
We wonder if the concept of comparing cancer staging systems using a reclassification table was adopted from the field of risk prediction, where there is often an ''old'' or established risk prediction model and a candidate ''new'' or ''updated'' risk model (which often adds a new biomarker to the old model). In this context, it has become common to cross-classify subjects with respect to ''old'' and ''new'' risk models using a reclassification table. 2, 3 While the reclassification table is an interesting exploratory tool, we and others have argued against the notion that a new risk model should be evaluated by the degree to which it reclassifies individuals compared to the old risk model. [4] [5] [6] In the end, the decision is which model or system to adopt for the relevant population, so we recommend that each candidate be evaluated in terms of its performance in that population. 7
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